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Abstract 
Integrin-mediated cell adhesion is involved in many essential normal cellular and pathological 
functions  including  cell  survival,  growth,  differentiation,  migration,  inflammatory  responses, 
platelet aggregation, tissue repair and tumor invasion. 24 different heterodimerized transmem-
brane integrin receptors are combined from 18 different α and 8 different β subunits. Each in-
tegrin subunit contains a large extracellular domain, a single transmembrane domain and a usually 
short cytoplasmic domain. Integrins bind extracellular matrix (ECM) proteins through their large 
extracellular domain, and engage the cytoskeleton via their short cytoplasmic tails. These integ-
rin-mediated linkages on either side of the plasma membrane are dynamically linked. Thus, integ-
rins communicate over the plasma membrane in both directions, i.e., outside-in and inside-out 
signaling. In outside-in signaling through integrins, conformational changes of integrin induced by 
ligand binding on the extracellular domain altered the cytoplasmic domain structures to elicit 
various intracellular signaling pathways. Inside-out signaling originates from non-integrin cell sur-
face receptors or cytoplasmic molecules and it activates signaling pathways inside the cells, ulti-
mately resulting in the activation/deactivation of integrins. Integrins are one of key family proteins 
for cell adhesion regulation through binding to a large number of ECM molecules and cell mem-
brane proteins. Lack of expression of integrins may result in a wide variety of effects ranging from 
blockage in pre-implantation to embryonic or perinatal lethality and developmental defects. Based 
on both the key role they played in angiogenesis, leukocytes function and tumor development and 
easy accessibility as cell surface receptors interacting with extracellular ligands, the integrin su-
perfamily represents the best opportunity of targeting both antibodies and small-molecule an-
tagonists for both therapeutic and diagnostic utility in various key diseases so far. 
Key words: Integrin, inside-out signaling, outside-in signaling, cell adhesion molecule, angiogene-
sis. 
1. INTRODUCTION 
Adhesion of cells to the surrounding extracellu-
lar  matrix  (ECM)  and  to  other  cells  is  essential  for 
tissue integrity, which have been crucial for the evo-
lution  from  protozoans  to  metazoans.  Integ-
rin-mediated cell adhesion to ECM plays a central role 
in the formation and remodeling of tissues and organs 
in  multicellular  organisms  [1-2].  Integrins  mediate 
cell-to-cell and cell-to-ECM adhesion, providing ad-
hesion  for  stationary  cells,  traction  during  cell 
movement and, importantly, the promotion of many Theranostics 2011, 1 
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signaling  pathways  that  regulate  diverse  processes 
including  proliferation,  migration, cell survival, dif-
ferentiation, tumor invasion and metastasis [3-4]. As a 
family  of  heterodimeric  transmembrane  receptors 
consisting of an α and a β subunit, 18 different α and 8 
different β subunits are known in mammals, which 
can combine to 24 different integrin receptors [5-6]. 
Some  subunits  can  combine  with  several  different 
partners,  adding  to  the  structural  complexity  of  in-
tegrin receptors. All these integrins can be segregated 
into two groups, one containing and the other lacking 
an  extra  von  Willebrand  factor  type  A  domain 
(vWFA,  known  as  αA  or  αI  in  integrins)  in  their 
α-subunits (Fig. 1). The composition and morphology 
of  integrin-dependent  adhesions  (focal  complexes/ 
podosomes, focal adhesions and fibrillar adhesions) 
vary with the cell type, matrix and integrin, and may 
switch  from  one  adhesion  contact  to  another,  con-
tributing to cell advancement, tissue remodeling and 
repair  [7].  Based  on  their  important  biological  and 
pathological function, integrins have been intensively 
investigated as imaging or therapy targets, which will 
be  discussed  in  details  in  the  following  chapters  of 
this book. The purpose of this chapter is to give an 
overall  description  of  the  structure,  expression  pat-
tern, and biological/pathological function of various 
integrins. 
 
Figure 1. The integrin superfamily. The integrins can be 
subdivided according to their β chains but note that some α 
chains can combine with several β chains. 24 different in-
tegrins are present in humans [8].  
 
2. INTEGRIN STRUCTURE 
Each integrin subunit contains a large extracel-
lular domain (N-terminus of >700 residues), a single 
transmembrane domain (>20 residues) and a usually 
short cytoplasmic domain (C-terminus of 13–70 resi-
dues)  [9].  The  I  (inserted)  domain  is  the  most  im-
portant  integrin  domain  in  ligand  recognition  [10]. 
For  integrins,  the  αI  domain  presents  in  approxi-
mately half of all α subunits and the βI domain pre-
sents in all β subunits. The αI domain is the primary 
ligand binding region in the integrins which have this 
domain. Whereas in integrins which lack the α I do-
main, the binding site in the integrin ―head‖ is formed 
by structural contributions of both the α and β chains 
[11]. αI is a GTPase-like domain in which the catalytic 
site  at  the  apex  is  replaced  with  a  conserved  met-
al-ion-dependent  adhesion  site  (MIDAS),  which  is 
occupied  by  a  divalent  cation.  All  of  the  integ-
rin–ligand  interfaces  analyzed  thus  far  have  had  at 
their center a coordinate bond between the integrin 
MIDAS and a carboxylate from the ligand and Mg2+ is 
the  physiological  metal  that  comprises  integrin 
MIDAS  [12].  αI  domains  have  been  crystallized  in 
three distinct conformations, termed closed, interme-
diate, and open, with coordination of the metal in the 
MIDAS,  arrangement  of  the  β6-α7  loop,  and  axial 
disposition of the C-terminal α7-helix along the side 
of the I domain [13-14]. Change in coordination at the 
MIDAS  of  α  I  domains  is  coupled  to  backbone 
movements of loops that bear the coordinating resi-
dues to increase complementarities to ligands (Figure 
2) [15].  
In the α2 I domain-collagen triple helical peptide 
structure  [16],  the  stiff  collagen  rod  docks  onto  a 
shallow trench on top of the I domain, with MIDAS 
situated  at  the  center,  coordinated  by  a  glutamate 
residue of collagen. Another major αI ligand class is 
comprised  of  cell  surface  molecule  intercellular  cell 
adhesion molecules (ICAMs). These are recognized by 
a β2 class of integrins that are exclusively expressed 
on leukocytes. This interaction is crucial in enabling 
leukocyte migration into sites of inflammation. Based 
on the structure of the ICAM-3-αL I domain solved by 
Song et al. [17], and the important structural deter-
minants  for  the  interaction  are  distributed  across  a 
rigid scaffold composed of a β sheet and a structurally 
constrained loop.  
When present, αI domain is situated at the top of 
the heterodimer and forms clear protrusions [18-19], 
whereas the βI domain folds together intimately with 
the β-propeller domain of the a subunit, constituting 
half of the large globular head [20]. The crystal struc-
ture  of  the  ectodomain  from  the  αI  domain-lacking 
integrin,  αvβ3,  was  also  determined  in  both  un-
liganded (in the presence  of Ca2+ or Mn2+) and lig-
and-bound states [11, 21]. As shown in Figure 3, αv 
consists of four domains: an N terminal seven-bladed 
β-propeller, an Ig-like Thigh domain and two large 
β-sandwich domains, Calf-1 and Calf-2. The β-subunit 
comprises  an  N-terminal  cysteine-rich  PSI           Theranostics 2011, 1 
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(Plexin-Semaphorin-Integrin)  domain  in  which  an 
Ig-like ―Hybrid‖ domain is inserted in its c-terminal 
loop (the Hybrid domain contains in turn an αA-like 
domain  (βA  domain)  inserted  between  its  two 
β-sheets). PSI is followed by four EGF-like domains 
and a membrane proximal novel tail domain (β-TD). 
The propeller and βA domains assemble into a ―head‖ 
structure,  which  accounts  for  formation  of  the  αβ 
heterodimer. The integrin head sits on top of an α and 
a β ―legs‖, formed respectively of the Thigh and Calf 
domains  from  the  αV-subunit  and  the  PSI,  Hybrid, 
EGF1-4 and βTD domains from the β3-subunit [11].  
The structure of liganded αvβ3 ectodomain was 
determined  after  diffusing  the  high  affinity  cyclic 
pentapeptide,  cilengitide,  which  contains  the  proto-
typical Arg-Gly-Asp (cRGD), into preformed integrin 
crystals in the presence of 5 mM Mn2+. RGD inserts 
into a crevice between the propeller and βA domains, 
with  the  residues  R  and  D  side  chains  exclusively 
contacting the propeller and βA domains, respective-
ly,  and  bringing  these  two  domains  closer  together 
[21]. The activating inward movement of α1 helix and 
rearrangement of the F/α7 loop seen in liganded α I 
are also observed in liganded β I, leading to similar 
although  much  less  dramatic  changes  in  the  three 
surface loops coordinating MIDAS and the SDL loop. 
Metal  coordination  at  ADMIDAS  changes  signifi-
cantly, such that it no longer locks the α1 helix to the 
F/α7  loop,  allowing  the  activating  movements  in 
both. The inward movement of α1 carries ADMIDAS 
with it, moving it closer to MIDAS, thus helping sta-
bilize the new metal ion at MIDAS [21]. 
 
Figure 2. Conformational change and transmission of allostery by α and β I domains. (a) The α I domain. Nonmoving 
segments of the backbone are shown as a gray worm. The moving segments of the backbone and the MIDAS metal ions are 
closed (gold) and open (cyan). The direction of movement is indicated with arrows. (b) The β I domain and its linkage to the 
hybrid and plexin/semaphorin/integrin (PSI) domain. Nonmoving segments of the β I backbone are shown as a gray worm. 
Moving segments and metal ions are color coded as shown. Directions of α1- and α7-helix movements are shown with 
arrows [18]. 
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Figure 3. Crystal structures of integrins αVβ3 and αIIbβ3. (a) The structure of αVβ3 in the bent conformation. The αV and 
β3 subunits are colored in green and red, respectively. (b) Superposition of liganded-open αIIbβ3 and unliganded-closed 
αVβ3 headpieces. The α and β subunits are colored in green and yellow in αVβ3 and in purple and light blue in αIIbβ3. 
Calcium and magnesium ions in αIIbβ3 only are gold and gray spheres, respectively [18]. 
 
Crystal  structures  of  the  αvβ3  ectodomain  in 
complex with the cyclic RGD peptide [21], as well as 
another RGD-type integrin (αIIbβ3) complexed with 
ligand  mimetic  compounds  [22]  have  revealed  that 
the  minimal  RGD  set  provides  two  essential  an-
chorpoints: one is the Asp carboxylate, which coor-
dinates directly the β MIDAS; the other is the Arg side 
chain (or basic moiety), which forms a salt bridge to 
an  acidic  residue  in  the  b-propeller  domain  of  the 
αv/αIIb subunit. In addition, these anchorpoints are 
located  at  the  bottom  of  the  narrow  cleft  or  ‗well‘, 
where the small ligand compounds are well accom-
modated,  burying  more  than  half  of  the  molecular 
surface  at  the  interface.  αvβ3  integrin  shows  little 
preference  in  its  choice  among  the  many 
RGD-containing proteins. Surprisingly, even the strict 
RGD sequence requirement rule can be bent [23]. For 
example, cells from homozygous knock-in mice car-
rying the RGD→RGE mutation in fibronectin exhib-
ited  normal  fibronectin  assembly  in  an 
αvβ3-dependent manner [24]. This observation indi-
cated that the positioning of both an acidic and basic 
residue in proper geometrical proximity is sufficient 
for  meaningful  affinity.  The  well-type  pocket  con-
taining β MIDAS seems specifically designed to ac-
commodate ‗loop ligand‘. Residues adjacent to RGD 
seem to provide some specificity toward certain in-
tegrins, both by making extra direct contacts and by 
changing the ‗width‘ of the RGD segment [25-26].  
Although  α  MIDAS  and  β  MIDAS  normally 
function in a tandem fashion in αI domain-containing 
integrins, they each could potentially engage two in-
dependent  external  ligands  simultaneously.  For  ex-
ample,  semaphorin  7A,  a  GPI-anchored  membrane 
protein that contains an RGD motif, was reported to 
promote  axon  outgrowth  through  b1  integrin(s), 
though the α subunit responsible for this activity was 
not  determined  [27].  Purified  a1b1  does  recognize 
semaphorin 7A in an RGD-dependent manner [28]. It 
is therefore tempting to speculate that RGD binds to 
the  β  MIDAS,  leaving  the  α  MIDAS  unoccupied. 
Laminins  are  major  basement  membrane  proteins 
composed  of  three  different  polypeptide  chains, 
termed a, b, and g. Till date, five a, three b, and three g 
chains are known to make up at least 15 isoforms of 
heterotrimeric laminins in mammals [29]. It has been 
reported  that  integrins  exhibited  a  distinct  laminin 
isoform  preference  [30].  Mutational  and  antibody 
mapping studies have revealed that C-terminal lam-
inin globular (LG) domains of the a chain, particularly 
LG1-3,  are  important  for  integrin  recognition  [31]. 
However,  recombinant  fragments  corresponding  to 
this region have not shown significant cell adhesion 
activity  comparable  to  that  of  intact  heterotrimeric Theranostics 2011, 1 
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laminins. Full integrin-binding activity of LG1-3 re-
quires  the  heterotrimeric  C-terminal  portion  of  the 
coiled-coil  domain,  including  the  most  distant 
C-terminal region of the b and g chains [32].  
Accumulating  evidence  supported  that  the 
structure changes of integrins are the basis of the in-
tegrin signaling. Indeed, negative stain electron mi-
croscopy  with  image  averaging  of  integrins  has 
shown three overall conformations of the extracellular 
domain and these correspond to a low affinity, bent 
conformation (as in the αvβ3 structure), an interme-
diate affinity, extended form with a closed headpiece, 
and  a  high  affinity,  extended  form  with  an  open 
headpiece, which is induced by ligand mimetic com-
pounds [22]. In integrins that lack the I-domain, the 
ligand  binds  directly  to  the  β  I-like  domain,  and 
causes a downward movement of its α7 helix, simi-
larly to what was described above for the integrin α 
I-domains. This shift results in a swing-out movement 
of the β chain hybrid and PSI domains and these do-
mains act as a rigid lever that transmits and amplifies 
the motion, resulting in a separation of the α and β 
legs and integrin extension [22]. On the other hand, 
the  swing-out  movement  of  the  upper  β  leg  could 
readily occur if it were preceded by extension of both 
legs.  
Several models have been proposed to integrate 
the  structural  changes  of  integrins  and  consequent 
biochemical  findings  [33].  For  example,  a  ―switch-
blade‖ model proposed that the head structure with 
the large (~ 80°) Hybrid swing-out represents the high 
affinity state of βA. To provide the necessary space for 
the  Hybrid  swing-out,  the  model  suggests  that  the 
integrin  first  fully  extend  its  knees,  converting  the 
bent into a linear asymmetric conformation, described 
as such in 2D EM images [19]. An alternate ―dead-
bolt‖  model  suggest  that  elastic  deformation  of  the 
F/α7 loop  is possible  with only modest  quaternary 
changes at the βTD interface with βA and possibly 
Hybrid  domains  [34].  It  has  been  found  that  upon 
binding of ICAM-5 to the LFA-1 I-domain, a remark-
able outward movement of the α7 helix was observed, 
which resulted in the replacement of the correspond-
ing α7 helix from a neighboring I-domain into the α7 
helix position, but in an upside-down configuration. 
This  α7  helix  replacement  was  further  propagated, 
resulting in a large I-domain/ICAM-5 cluster. In this 
way, a weak initial interaction between the integrin 
and a ligand can result in the formation of large lig-
and/receptor aggregates [35].  
3. INTEGRIN SIGNALING 
Integrins bind ECM proteins through their large 
extracellular domain, and engage the cytoskeleton via 
their short cytoplasmic tails. These integrin-mediated 
linkages on either side of the plasma membrane are 
dynamically linked. The cytoskeleton controls affinity 
and  avidity  of  the  integrin  extracellular  domain  to 
modulate  the  ECM,  and  integrin  binding  to  ECM 
changes the shape and composition of the cytoskele-
ton beneath  [36]. Thus, integrins communicate over 
the  plasma  membrane  in  both  directions,  i.e.,  out-
side-in  and  inside-out  signaling  [18].  In  outside-in 
signaling through integrins, ligands bind to extracel-
lular  integrin  domains,  where  a  conformational 
change occurs so that the signal is transmitted into the 
cell.  Integrin  clustering  may  also  occur.  Inside-out 
signaling  originates  from  non-integrin  cell  surface 
receptors  or  cytoplasmic  molecules  and  it  activates 
signaling  pathways  inside  the  cells,  ultimately  re-
sulting in the activation/deactivation of integrins. In 
this case, adhesion may be regulated both by confor-
mational  changes  in  the  integrin  and  by  valency 
change  (integrin  clustering).  In  fact,  both  signaling 
events may occur simultaneously and reinforce each 
other [8]. 
Changes in interactions and/or in the structures 
of  the  cytoplasmic  domains  of  integrins  within  the 
membrane-proximal regions play crucial roles in in-
tegrin  activation  via  inside-out  signaling  [37-38]. 
Conformational changes of integrin induced by ligand 
binding on the extracellular domain altered the cyto-
plasmic domain structures to elicit various  intracel-
lular  signaling  pathways.  A  prominent  biochemical 
event in integrin outside-in signaling is protein tyro-
sine phosphorylation due to activation of Src and FAK 
family  protein  tyrosine  kinases  [39-40].  Src  and  its 
inhibitory Csk are constitutively bound to the integrin 
β-tails. Integrin binding to ligand induces Src activa-
tion through Csk dissociation, Src transphosphoryla-
tion and/or recruitment of tyrosine phosphatases (e.g 
receptor tyrosine phosphatase RPTPα, or PTP-1B [39]. 
However, the spatiotemporal and structural basis of 
the interaction of integrin cytoplasmic-tails with the 
growing  list  of  signaling  molecules  including  cyto-
solic  and  receptor  kinases  (Src,  FAK,  Syk,  ILK  and 
PKC) and phosphatases remains to be determined [9].  
The integrin cytoplasmic domains play a central 
role in integrin activation [41-42]. However, the short 
integrin cytoplasmic tails lack enzymatic activity, and 
so depend on recruitment of adaptor molecules and 
signaling proteins for effector functions [36]. Talin is a 
major cytoskeletal protein that co-localizes with and 
binds to integrins and to actin and actin-binding pro-
teins such as vinculin [43]. It has been demonstrated 
that binding of talin to the β cytoplasmic domain is a 
crucial,  final  step  in  activation  of  several  classes  of 
integrins  [44-45].  Knockdown  of  talin  expression  in Theranostics 2011, 1 
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CHO (Chinese-hamster ovary) cells inhibits the acti-
vation of both  β1 and  β3 integrins without altering 
integrin  expression  [44].  NMR  studies  suggest  that 
direct disruption of α–β tail interaction by the talin 
head  domain  result  in  integrin  activation  [46].  Pro-
posed  a  two-step  activation  model,  the  talin  head 
domain first recognizes the high-affinity binding site 
in  the  membrane-distal  region,  which  provides  a 
strong linkage between the talin and the integrin  β 
tail, and subsequently binds to a second lower-affinity 
membrane proximal site that is involved in α–β asso-
ciation, triggering separation of the tails and integrin 
activation  [47-48].  Although  talin  is  an  important 
player in integrin activation mechanisms, the possi-
bility remains that other integrin tail-binding proteins 
can  substitute  for  talin.  For  example,  many  other 
PTB-domain-containing  proteins  including  Numb, 
Dok-1, ICAP-lα (integrin cytoplasmic domainassoci-
ated protein-lα) and Kindlins bind to integrin β tails 
in a similar fashion to talin [49]. 
Integrin  activation  requires  transmission  of 
conformational rearrangements from the cytoplasmic 
face to the extracellular domain. The interaction be-
tween the membrane-proximal regions of the α and β 
subunits is believed to be stabilized by a salt bridge 
between a conserved arginine residue in the α tail and 
an aspartate residue in the β tail and by the hydro-
phobic residues immediately N-terminal to the argi-
nine and aspartate residues [50]. Mutations that dis-
rupt this ‗clasp‘ lead to integrin activation, and integ-
rins  can  be  constitutively  activated  by  deletion  or 
mutations  in  these  membrane-proximal  sequences 
[42].  These  data  together  strongly  indicate  that  this 
membrane-proximal  interaction  plays  an  essential 
role as a stabilizer in the association of the α and β 
membrane  proximal  regions,  maintaining  the  integ-
rins  in  a  low-affinity  state.  In  addition,  mutational 
analysis  and  computational  modeling  together  sug-
gest that a helical interface between the integrin α and 
β subunit transmembrane domains stabilizes the in-
active state, and suggest that disruption of this helical 
transmembrane interface leads to activation [51] [52]. 
4. LIGANGDS OF INTEGRINS 
The  majority  of  integrin  ligands  are  protein 
components  of  ECM  (Table  1).  ECM  is  assembled 
from components synthesized and deposited outside 
the cell surface that provide structural and functional 
integrity  to  connective  tissues  and  organs  [53].  The 
ECM can also serve as a reservoir or provisional ma-
trix for growth factors and plasma proteins found in 
the blood [54]. The protein components of ECM can be 
divided  into  three  major  classes:  (1)  structural  pro-
teins such as the collagens and elastin (although col-
lagen  can  also  have  functional  properties);  (2)  mul-
tidomain adhesive glycoproteins such as fibronectin, 
vitronectin,  and  laminin;  and  (3)  matricellular  pro-
teins such as secreted protein acidic and rich in cys-
teine (SPARC; also known as osteonectin and BM-40), 
thrombospondin  1  (TSP1)  and  2  (TSP2),  tenascin  C 
and X, and osteopontin [53]. Among them, collagen 
primarily provides tensile strength to the tissue and 
elastin is responsible for the elastic recoil. Fibronectin, 
an adhesive glycoprotein, is a multifunctional protein 
that can act as a structural molecule owing to its fi-
brillar  architecture,  a  biological  glue  that  mediates 
interactions between cells and other ECM proteins, or 
a bridge forming cell to cell contacts [55]. Matricellu-
lar proteins are secreted macromolecules that interact 
with cell-surface receptors, ECM, growth factors, and 
proteases but do not function as structural molecules 
per se [56]. These glycoproteins regulate interactions 
between cells and ECM. For instance, SPARC, TSP1, 
and tenascin C disrupt cell–matrix interactions (i.e., 
are counteradhesive) — a critical component of angi-
ogenesis and tissue remodeling [57].  
All five αV integrins, two β1 integrins (α5, α8) 
and αIIbβ3 share the ability to recognize ligands con-
taining an RGD tripeptide active site, which is shared 
by The RGD binding integrins are among the most 
promiscuous in the family, with β3 integrins in par-
ticular binding to a large number of ECM and soluble 
vascular  ligands  including  fibronectin,  fibrinogen, 
vitronectin,  vWF,  LAP-TGFβ  and  Del-1.  Although 
many ligands are shared by this subset of integrins, 
the rank order of ligand affinity varies, presumably 
reflecting the preciseness of the fit of the ligand RGD 
conformation with the specific α-β active site pockets 
[58]. 
Collagens are a major family of structural ECM 
proteins and characterized by the presence of triple 
helical regions. Cells employ four different αI domain 
containing integrins including α1, α2, α10, and α11 to 
maintain  holds  with  them.  Immunoglobulin  super-
family members also act as ligands for several integ-
rins, and the best characterized integrin ligands are 
VCAM-1 (Vascular Cell Adhesion Molecule) and the 
ICAMs.  VCAM-1  binds  to  α4β1,  αVβ3  and  α4β7, 
whereas the leukocyte-specific CD11/CD18 integrins 
(including LFA-1 and Mac-1) bind to ICAMs [59]. 
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Table 1. Ligands and distribution of integrins  
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5. BIOLOGICAL AND PATHOLOGICAL 
FUNCTION OF INTEGRINS 
Cell  adhesion  is  involved  in  many  essential 
normal cellular and pathological functions including 
cell  survival,  growth,  differentiation,  migration,  in-
flammatory  responses,  platelet  aggregation,  tissue 
repair and tumor invasion. Integrins are one of key 
family proteins for cell adhesion regulation through 
binding  to  a  large  number  of  extracellular  matrix 
molecules  and  cell  membrane  proteins.  Using 
knockout mice it has become evident that the integ-
rins possess both redundant and nonredundant func-
tions, and that lack of expression may result in a wide 
variety  of  effects  ranging  from  blockage  in 
pre-implantation  to  embryonic  orperinatal  lethality 
and developmental defects.  
β1 Integrin. The largest subgroup of integrins is 
formed by the β1 subunit containing integrins which 
consist of 12 members with different ligand binding 
properties.  Besides  ECM  proteins,  some  β1  integrin 
containing receptors also interact with cellular recep-
tors. For example,  α4β1 and α9β1 bind to VCAM-1 
and α4β1 to MadCAM-1 [60]. During early embryo-
genesis  totipotent  embryonic  cells  differentiate  and 
polarize  to  form  endoderm,  basement  membrane 
(BM), and ectoderm. However, embryoid bodies de-
rived from β1-deficient ES cells develop endoderm, 
but do not form a BM, polarized ectoderm and a cav-
ity [61]. β1-integrin null embryos die by embyronic 
day (E)9.5–10.5 in utero owing to implantation defects 
[62-63]. The major function of β1 integrin during early 
development may be to induce laminin-1 expression 
since  exogenous  addition  of  laminin  1  allows  BM 
formation also in the absence of β1 integrins, though 
the signaling pathway mediating the regulation is still 
unclear  [64].  β1  integrins  are  crucial  for  the  attach-
ment of basal keratinocytes to the BM, since loss of β1 
leads  to  widespread  blisters  between  the  epidermis 
and the BM. In addition, loss of β1 integrin in skin 
decreases the proliferation of basal keratinocytes by 
about  70%  [65].  Similarly  to  skin,  β1  integrins  are 
important for the attachment to and maintenance of 
the BM in brain [66]. Although β1 integrins are im-
portant  ECM  receptors,  they  are  not  generally  re-
quired for cell migration. While some cells, such as 
keratinoctes or primordial germ cells, are highly de-
pendent  on  β1  integrin,  other  such  as  myoblasts, 
neurons  and  lymphocytes  migrate  normally  also  in 
the absence of β1 integrin. Tumor cells expressing β1 
integrin  formed  significantly  larger  primary  tumors 
and had a dramatically increased metastasis into liver 
and lung [67]. Moreover, ablation of the β1 integrin 
gene  in  mammary  epithelium  dramatically  impairs 
mammary  tumorigenesis  in  mice  [68].  However,  in 
human patients, no clear correlation between tumor 
formation, invasion and β1 integrin expression could 
be identified yet. 
Integrins α1β1 and α2β1 are expressed on lym-
phatic endothelium in healing wounds in response to 
VEGF.  Inhibition  of  these  integrins  blocked  lym-
phangiogenesis in these wounds [69]. In normal ani-
mals,  VEGFA  treatment  upregulates  expression  of 
both  α1β1  and  α2β1  on  vascular  endothelial  cells. 
Function-blocking  antibodies  directed  against  both 
integrins  reduced  VEGFA-induced  angiogenesis  in 
vivo  and  reduced  tumor  growth  and  angiogenesis 
[70]. Tumors grown in α1β1-deficient mice grew more 
slowly and exhibited less angiogenesis, indicating an 
important role for this integrin in angiogenesis [71]. 
However,  mice  lacking  α2β1  integrins  exhibit  in-
creased B16F10 melanoma growth and angiogenesis 
when compared with wild-type mice [72]. By contrast, 
Lewis lung carcinoma (LLC) tumors did not exhibit 
increased angiogenesis or growth in α2-null mice. The 
different response resulted from different level of a 
VEGFR1 binding placental growth factor (PLGF) ex-
pression which was high from B16F10 melanoma cells 
and low from LLC cells. Enhanced angiogenesis was 
attributed to an increase in VEGFR1 expression and 
function on α2-null endothelial cells [72].  
Integrin α4β1, a receptor for VCAM and fibron-
ectin containing the CS1 region, is best known as a 
lymphocyte  integrin  involved  in  adhesion  and  ex-
travasation  of  lymphocytes  by  binding  to  VCAM1 
which is expressed on inflamed endothelial cells. Loss 
of integrin α4 during development leads to defects in 
placentation, heart development and coronary artery 
development,  causing  lethality  between  E10.0  and 
E12.0 [73]. It has been reported that integrin α4β1 was 
expressed  on  neo-vasculatures  in  both  murine  and 
human  tumors  and  responded  to  VEGF,  bFGF,  IL1 
and  TNF.  Antagonists  of  α4β1  blocked  tumor  neo-
vascularization by induction of cell death of both en-
dothelial  cells  and  pericytes  and  decreased  tumor 
growth in chick and murine models of tumor growth 
[74]. It has been proposed that integrin α4β1–VCAM1 
interactions  facilitated  close  proximity  of  the  endo-
thelial cells and pericytes, which promoted the sur-
vival  of  both  endothelial  cells  and  pericytes  during 
angiogenesis [74]. Moreover, integrin α4β1 selectively 
promotes the homing of both endothelial progenitor 
cells  and  monocytes  to  neovascular  tissue  [75]. 
Treatment of mice bearing LLC tumors with antago-
nists  of  integrin  α4β1  significantly  suppressed  the 
number  of  monocytes  and  progenitor  cells  found 
within tumors and reduced blood vessel density [76], 
indicating  that  the  suppression  of  monocyte  and Theranostics 2011, 1 
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progenitor  cell  homing  to  tumors  by  integrin  α4β1 
antagonists  could  be  a  useful  supplementary  ap-
proach to suppress tumor angiogenesis and growth.  
Embryonic  deletion  of  the  integrin  α5  subunit 
induces early mesenchymal abnormalities, leading to 
lethality of α5-null embryos [77]. Further studies us-
ing α5-null ES cells to grow teratocarcinomas showed 
decreased proliferation, increased apoptosis and de-
creased  vascularization  in  teratocarcinomas  derived 
from  α5-null  ES  cells  compared  with  controls  [78]. 
Integrin α5β1 expression is induced in response to a 
variety of angiogenic stimuli, such as bFGF, IL8 and 
the ECM protein DEL1 (also known as EDIL3), but not 
by  VEGF  [79].  Integrin  α5β1-mediated  adhesion 
promotes endothelial cell  migration and survival  in 
vivo and in vitro by suppressing the activity of protein 
kinase A (PKA) [80]. Integrin α5β1 is poorly expressed 
on quiescent endothelium but its expression is signif-
icantly  upregulated  on  endothelium  during  tumor 
angiogenesis in both mice and humans [81]. In some 
types  of  cancer,  integrin  α5β1  is  also  expressed  on 
tumor cells and plays a direct role in tumor cell mi-
gration, invasion, and survival [82-84]. A small pep-
tide antagonist (amino-acid sequence PHSCN) to in-
tegrin α5β1 significantly reduced neovascularization 
and formation of metastases in an animal model of 
prostate carcinoma that expresses integrin α5β1 [83, 
85-86]. Expression of α5β1 is also upregulated during 
corneal angiogenesis [87]. 
Integrin α6β1 is expressed at high levels in ca-
pillary  endothelial  cells  in  vivo  [88].  Unlike  α6β4, 
which shows a preference for laminin 5, integrin α6β1 
binds  most  laminin  isoforms  as  well  as  other  ECM 
proteins  including  CYR61,  thrombospondin  1  and 
thrombospondin  2  [89].  As  α6  integrin  antagonists 
and α6 small interfering RNA constructs inhibit an-
giogenesis, it is possible that integrin α6β1 promotes 
angiogenesis. However, as these agents can block the 
function of both integrins α6β1 and α6β4, it is not yet 
clear what part integrin α6β1 plays in tumor angio-
genesis [88]. Antibody inhibitors of α6 integrin pre-
vented endothelial cell tube formation  in vitro, sug-
gesting a role for α6 in the angiogenic process [88]. 
Integrin α9β1 is structurally similar to integrin 
α4β1.  However,  unlike  α4β1,  it  is  a  receptor  for  a 
number  of  ECM  proteins  and  cell  surface  receptors 
including  tenascin  C,  thrombospondin,  osteopontin, 
IIICS fibronectin, VCAM1 and other ligands [90]. In-
tegrin  α9β1  is  expressed  on  epithelia,  osteoclasts, 
smooth muscle cells and also endothelial cells. α9β1 
promotes VEGFA-stimulated angiogenesis by directly 
binding to VEGFA and blocking antibodies to α9β1 
suppress VEGFA-induced angiogenesis [91]. Howev-
er, other studies found that α9β1 also binds directly to 
the N terminus of thrombospondin and blocking an-
tibodies  to  α9β1  inhibited  angiogenesis  induced  by 
this  thrombospondin  fragment  [92].  Integrin  α9β1 
also has a role in growth factor-mediated lymphan-
giogenesis  as  PROX1,  a  lymphatic  endothelial 
cell-selective  transcription  factor,  coordinately  up-
regulates integrin α9β1 and VEGFR3 expression and 
endothelial  cell  motility  in  vivo  [93].  This  integrin 
promotes  VEGFC-  and  VEGFD-stimulated  cell  mi-
gration by directly binding these growth factors and 
antagonism of α9β1 suppresses VEGFC-induced mo-
tility [94]. Taken together, these studies indicate that 
α9β1  has  unique  and  crucial  roles  in  lymphangio-
genesis. Indeed, integrin α9β1-null mice die 8–12 days 
after birth owing to lethal defects in development of 
the lymphatic system; however, they do not exhibit 
obvious defects in development of blood vessels [95].  
αvβ3 Integrin. The integrin αvβ3 is the first of the 
αv integrins to be characterized and shown to regu-
late  angiogenesis  [96-97].  It  binds  with  multiple 
components  of  the  ECM  including  vitronectin,  fi-
bronectin, fibrinogen and osteopontin since they are 
all RGD-containing proteins. It has been found in 1994 
that  integrin  αvβ3  was  widely  expressed  on  blood 
vessels in human tumor biopsy samples but not on 
vessels  in  normal  human  tissues.  Its  expression  on 
endothelial cells is stimulated by angiogenic growth 
factors such as bFGF, TNFα and IL8 and it is upregu-
lated on endothelium in tumors, wounds and sites of 
inflammation αvβ3 integrin has a key role in endo-
thelial cell survival and migration during angiogene-
sis [96] [98]. Antagonists of αvβ3 inhibited angiogen-
esis and tumor growth in a variety of animal models 
of  cancer  and  blocked  corneal  as  well  as  choroidal 
angiogenesis  in  animal  models  of  ocular  disease 
[98-99]. In addition, integrin αvβ3 antagonists induce 
endothelial  cell  apoptosis  through  a  caspase 
8-dependent cell death program [100]. In vitro studies 
revealed that agonists of endothelial cell αvβ3, but not 
other  integrins,  suppressed  p53  activity,  blocked 
p21WAF1/CIP1  expression,  and  increased  the 
bcl-2/bax ratio, thereby promoting cell survival [101]. 
Ligation  of  endothelial  αvβ3  integrin  has  also  been 
shown  to  activate  mitogen-activated  protein  kinase 
(MAPK), FAK and Src, among other kinases, resulting 
in  cell  proliferation,  differentiation  and  migration 
[102]. 
Based on the sizable body of evidence addressed 
above,  it  is  reasonable  to  draw  the  conclusion  that 
integrin αvβ3 promotes angiogenesis and endothelial 
cell  survival  and  that  antagonism  of  this  integrin 
suppresses angiogenesis by inducing endothelial cell 
apoptosis in vitro and in vivo. Indeed, antagonists of β3 
integrin  are  being  used  in  clinical  trials  as  an-Theranostics 2011, 1 
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ti-angiogenic  therapy,  including  the  humanized 
monoclonal antibody Vitaxin and the RGD mimetic 
Cilengitide [103-104]. However, these agents did not 
appear to be as successful at inhibiting angiogenesis 
in  clinical  trials  for  cancer  treatment  as  originally 
hoped [105]. Recently, it has been reported that low 
concentrations  of  RGD-mimetic  integrin  inhibitors 
promote  VEGF  mediated  angiogenesis  by  altering 
αvβ3 integrin and vascular endothelial growth factor 
receptor-2  trafficking,  thereby  stimulating  tumor 
growth and angiogenesis [106].  
More  importantly,  a  series  of  genetically 
Knock-out studies forced researchers to reconsider the 
role of integrin αvβ3 and αvβ5 in angiogenesis. For 
example, genetic ablation of the αv integrin subunit 
did not appear to affect developmental angiogenesis 
[107].  Even  conditional  deletion  of  αv  integrin  in 
Tie2-expressing  endothelial  cells  is  not  sufficient  to 
affect angiogenesis either [108]. Furthermore, β3 null 
and  β3/β5  doubly  deficient  mice  produce  vascular 
networks  without  obvious  defects  during  develop-
mental angiogenesis, and more surprisingly, display 
enhanced tumor growth and pathological angiogene-
sis [109-110]. However, male mice lacking β3 integrin 
exhibit  coronary  capillaries  of  irregular  endothelial 
thickness,  with  endothelial  protrusions  into  the  lu-
men, and expanded cytoplasmic vacuoles. These de-
fective  coronary  vessels  can  be  normalized  by  ad-
ministration of inhibitors of VEGF or VEGF receptor 2 
(VEGFR2, also known as KDR), suggesting that en-
hanced VEGF signaling might compensate for the loss 
of β3 integrin [111]. In addition, with a mouse knockin 
model, it has been demonstrated that the phosphory-
lation of Tyr747 and Tyr459 in β3 integrin participates 
in enhancing pathological angiogenesis [112]. 
All  considered,  the  above  studies  suggest  that 
avβ3  integrin  may  have  both  positive  and  negative 
roles  during  angiogenesis.  Indeed,  avβ3  can  bind  a 
plethora of factors that are thought to enhance angi-
ogenesis including VEGFR2, vitronectin, fibronectin, 
Del1, ANGPTL3, CYR61, bone sialoprotein, thrombin, 
and can also bind to several factors that are thought to 
induce  anti-angiogenic  effects  including  thrombos-
ondin, angiostatin, and tumstatin [113]. Another ex-
planation is that functioning as a biosensor, avβ3 may 
promote angiogenesis in the ligated state, but when 
ligands are absent or ligand binding is antagonized, 
avβ3 may activate a death pathway to inhibit angio-
genesis.  Thus,  depending  on  the  microenvironment 
and  the  ligation  state,  integrins  promote  or  inhibit 
angiogenesis  by  positively  or  negatively  regulating 
cell survival [114]. In this way, integrin avβ3 appears 
to function as a regulator of angiogenesis by balancing 
opposing signals in the tumor microenvironment. 
αvβ5  integrin.  All  though  integrin  αvβ5  binds 
with similar ECM components with αvβ3, the related 
angiogenic promoting pathway is distinct from that 
regulated by αvβ3. For example, anti-αvβ3 antibodies 
blocked angiogenesis induced by bFGF, whereas an-
tibodies  that  target  αvβ5  blocked  the  angiogenesis 
induced  by  VEGF  in  both  the  rabbit  corneal  eye 
pocket and the chick chorioallantoic membrane assay 
[115]. The VEGF– αvβ5 pathway is dependent on Src 
kinase  and  protein  kinase  C30. In vivo angiogenesis 
assays  showed  αvβ5  is  required  for  TGF-  β  and 
VEGF-mediated  angiogenesis  and  VEGF  acted 
through αvβ5 to promote vascular permeability [116], 
indicating αvβ5 may also promote tumor metastasis 
[117]. However, integrin αvβ5-null mice exhibit com-
pletely normal development and normal angiogenesis 
[118], indicating that this integrin is not required for 
vascular development. 
Genetic ablations of the αv subunit, which elim-
inate expression of integrins αvβ1, αvβ3, αvβ5, αvβ6 
and αvβ8 suggest that, in some mice, αv integrins are 
not  required  for  blood  vessel  development  in  most 
tissues. Twenty percent of embryos lacking αv integ-
rins  survive  to  birth  with  normal  blood  vessels  in 
many tissues. However, 80% of mice die in utero be-
tween E10.5 and E11.5 with defective placental blood 
vessels.  The  remaining  20%  of  αv-null  mice  die 
shortly  after  birth  with  severe  brain  and  intestinal 
haemorrhage,  with  distended  and  leaky  vessels  in 
these tissues [107]. Thus, αv integrins appear to have 
key roles in embryonic development of blood vessels 
in tissues such as placenta and brain. 
αvβ6  integrin.  The  αvβ6  receptor  is  the  only 
known  integrin  that  is  restricted  exclusively  to  epi-
thelial cells [119]. The αvβ6 integrin is expressed pri-
marily  during  embryonic  development  and  is  not 
expressed constitutively in healthy epithelia. Howev-
er,  αvβ6  is  upregulated  during  tissue  remodeling, 
including  wound  healing  and  carcinogenesis  [120]. 
αvβ6 facilitates keratinocyte adhesion and migration 
on fibronectin, tenascin and vitronectin, all of which 
are components of the early wound matrix [121]. Us-
ing mouse β6-/- keratinocytes, Huang et al. found that 
αvβ6  expression  promotes  keratinocyte  migration 
through a pathway involvling protein kinase C [122]. 
Binding of αvβ6 to its ligand upregulated secretion of 
the pro-enzyme form of type IV collagenase, MMP-9, 
and exogenous activation of MMP-9 further increased 
keratinocyte  migration  [123].  Thomas  et  al.  demon-
strated that binding of αvβ6 to the TGFb1 latency as-
sociated peptide (LAP) promotes cell migration and 
MMP-9  expression,  and  also  that  cells  will  invade 
towards soluble LAP in an αvβ6-dependent manner 
[124]. In addition, TGFb1 induces de novo expression Theranostics 2011, 1 
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of αvβ6 in normal human keratinocytes [125] and on 
the  non-transformed  keratinocyte  cell  line,  HaCaT 
[126].  
To date, αvβ6 expression has been reported in 
carcinomas  of  the  lung,  breast,  pancreas,  stomach, 
colon, ovary, salivary gland as well as oral and skin 
squamous  cell  carcinoma  [120,  127-131].  Elevated 
αvβ6 expression facilitated the invasion and dissem-
ination of colon carcinoma cells in vivo [132-133]. The 
β6  overexpressing  cell  line  was  significantly  more 
invasive,  which  was,  in  part,  through 
αvβ6-dependent  upregulation  of  the  type  IV  colla-
genase MMP-9 [134-135]. High αvβ6 expression cor-
related  with  elevated  uPA,  uPAR  and  MMP-9  in 
ovarian  carcinoma  cell  lines  [136].  It  has  also  been 
proposed  that  contribution  of  αvβ6  for  promoting 
cancer progression in vivo is related to the mechanism 
of epithelial–mesenchymal transition (EMT) by acti-
vating latent TGF-b [137]. The upregulation of αvβ6 
related with the poor prognosis [132], suggesting that 
αvβ6 expression may be useful in predicting malig-
nant transformation. Indeed, the integrin αvβ6 now 
emerges  as  an  attractive  new  candidate  as  a  thera-
peutic target for metastatic colon carcinoma. Howev-
er,  epithelial  cells  in  samples  of  lichen  planus  (a 
chronic  mucocutaneous  disease)  have  also  been 
shown to express αvβ6 suggesting that αvβ6 expres-
sion per se is insufficient to drive malignant progres-
sion [138]. The net effect on tumor behavior is likely to 
depend  on  the  stage  of  tumor  development.  In  the 
later  stages  of  tumor  development,  as  cells  become 
refractory to growth inhibition, then the role of LAP in 
promoting both αvβ6-dependent cell movement and 
MMP-9  expression  may  become  prominent,  culmi-
nating in a pro-oncogenic effect of TGFb [139].  
α6β4 Integrin. α6β4 plays a key role in the for-
mation and stabilization of junctional adhesion com-
plexes  called  hemidesmosomes  (HDs)  that  are  con-
nected  to  the  intermediate  filament  (IF)  system,  as 
well as in the regulation of a variety of signaling pro-
cesses. Increased expression of α6β4 and changes in 
its  distribution  were  then  correlated  with  increased 
aggressiveness of tumors and poor prognosis [140]. β4 
subunit has an unusual size of approximately 200 kDa, 
which is due to an unusually long cytoplasmic do-
main  of  over  1,000  amino  acids  [141].  This  domain 
contains two pairs of type III fibronectin (FNIII) do-
mains, separated by a connecting segment (CS) [142]. 
β4 knockout mice developed severe blistering of the 
skin [143]. Moreover, a mutation in the β4 gene is re-
sponsible for the pyloric atresia associated with junc-
tional  epidermolysis  bullosa  (EB)  syndrome  in  hu-
mans. It has been found that interaction between α6β4 
and plectin is critical for proper HD assembly and at 
least two sites on plectin and three on β4 mediate their 
interaction. The actin binding domain (ABD) of plec-
tin binds to the first pair of FNIII domains and part of 
the CS of β4 [144]. Two other HD components, BP180 
and BP230, bind to the third FNIII domain of β4 and 
to a region comprising the C-terminal end of the CS 
and  the  second  pair  of  FNIII  domains,  respectively 
[145]. The α6 subunit of α6β4 interacts with the tet-
raspanin CD151 [146]. 
Apart from promoting keratinocytes migration, 
studies on the invasion of carcinoma cells revealed a 
role for α6β4-dependent activation of phosphatidyl-
inositol (PI)-3 kinase, which is an upstream regulator 
of Rac1 [147]. Since growth factors activate enzymes 
that initiate the disassembly of HDs, the presence of 
overactive growth factor receptors may explain why 
α6β4 is unable to initiate HD formation in many car-
cinoma  cells.  In  fact,  α6β4  cooperates  with  several 
different tyrosine kinases  in carcinoma cells to pro-
mote  invasion,  including  c-met  (hepatocyte  growth 
factor receptor), ErbB2 and ErbB1 [148]. There is evi-
dence  that  proteins  other  than  tyrosine  kinases  can 
cooperate with α6β4 to promote invasion. For exam-
ple, invasion of breast carcinoma cells is stimulated by 
promoting  Rab11-mediated  vesicular  trafficking  un-
der hypoxic conditions [149]. 
Leukocytes specific integrins. The arrest of leuko-
cytes rolling on target vascular beds involves rapid 
formation of shear-resistant adhesions by specialized 
leukocyte  integrins.  This  arrest  can  be  mediated  by 
integrins that contain the β2 subunit, e.g. aLβ2 (leu-
kocyte  functionassociated  antigen-1  (LFA-1))  or  α4 
subunit,  e.g.  α4β1  (very  late  antigen-4  (VLA-4)).  In 
leukocytes,  integrins  are  involved  in  slow  rolling, 
adhesion strengthening, and transendothelial migra-
tion  [150-151].  Lymphocyte  and  myeloid  cells  cease 
rolling  and  arrest  on  lymph  node  high  endothelial 
venules as well as on peripheral tissues upon activa-
tion of at least one of the four major leukocyte integ-
rins:  VLA-4,  α4β7,  LFA-1,  and  the  myeloidspecific 
integrin  (integrin  αMβ2  (Mac-1))  [152].  In  addition, 
these integrins transmit signals that facilitate respira-
tory  burst,  complement-mediated  phagocytosis,  cy-
tokine production, proliferation, survival, differentia-
tion, degranulation, and cellular polarization. Loss or 
reduced  β2  on  cell  surface,  defects  in  β2  signaling, 
mutations in β2 will cause leukocyte adhesion defi-
ciencies (LAD) [153].  
Most  circulating  leukocytes  maintain  their  in-
tegrins in largely low affinity state [154]. Leukocyte 
integrins must undergo in situ modulation to develop 
high avidity for their endothelial ligands to establish 
shear-resistant adhesion and firm leukocyte arrest on 
the target endothelial site [155]. For most leukocytes, Theranostics 2011, 1 
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this dramatic change in integrin affinity is triggered 
when  the  rolling  leukocyte  encounters  and  rapidly 
responds  to  a  proper  chemoattractant  signal  pre-
sented  on  the  apical  endothelial  surface  [156].  The 
distribution of LFA-1 integrins to the leading edge of 
a polarized leukocyte is reported to proceed through a 
signaling cascade involving Rap1 and its downstream 
effectors RAPL and the threonine–serine kinase, Mst1 
[157].  Integrins  play  key  roles  in  cellular  migration 
acting both as adhesive molecules that maintain lo-
comotion over the apical endothelial surface and as 
signaling molecules, which, together with chemokine 
signals, maintain polarity and motility [158].  
Leukocyte  integrins  are  recognized  therapeutic 
targets  in  various  diseases,  and  integrin  blocking 
monoclonal  antibodies  (natalizumab  against  α4  in-
tegrins  and  efalizumab  against  LFA-1)  are  already 
used in the clinic against multiple sclerosis and pso-
riasis [159-160]. Leukocyte adhesion cannot be inhib-
ited by compounds containing the RGD sequence, but 
longer  peptides  to  recognition  sites  in  ICAM  mole-
cules or microbe-derived ICAM-1 inhibitors do show 
inhibitory activity [161-162]. It has been reported that 
promatrix  metalloproteinases  (proMMPs),  particu-
larly proMMP-9, are potent ligands of the leukocyte 
β2  integrins  and  translocating  proMMP-9/  αMβ2 
complex is part of the cell surface machinery guiding 
neutrophil migration [163], suggesting that a promis-
ing therapeutic approach could be to disrupt the as-
sociation  between  the  matrix  metalloproteases  and 
integrins. It has also been found that the Del-1 protein 
is  an  important  endogenous  inhibitor  of  leukocyte 
adhesion [164]. The Del-1 protein is a secreted protein 
expressed  by  endothelial  cells  in  immunoprivileged 
tissues, such as the brain, the eye, and the lung. Alt-
hough  a  secreted  molecule,  Del-1  is  absent  from 
plasma  and  is  rather  localised  to  endothelial  cells 
and/or the extracellular matrix [164]. In fact, it binds 
to the β2 integrins (LFA-1, Mac-1) and when coated on 
plastic,  leukocytes  adhere  to  the  protein.  However, 
leukocyte binding to ICAM-1 is inhibited when both 
Del-1 and ICAM-1 are present. Del-1 knockout mice 
show a strong activation of adhesion and of inflam-
matory cell recruitment [164].  
6. PERSPECTIVES OF INTEGRINS AS 
IMAGING AND THERAPY TARGETS 
Integrins are ideal pharmacological targets based 
on  both  the  key  role  they  played  in  angiogenesis, 
leukocytes function and tumor development and easy 
accessibility as cell surface receptors interacting with 
extracellular  ligands  [1].  So  far,  the  integrin  super-
family  represents  the  best  opportunity  of  targeting 
both  antibodies  and  small-molecule  antagonists  for 
both therapeutic and diagnostic utility in various key 
diseases  [165].  Preclinical  studies  and  clinical  trials 
showed that quite a few integrin targeting antibodies 
were effective to block tumor growth and metastasis. 
Most  of  studies  focused  on  αv  integrins  including 
MEDI-522  (vitaxin)  against  αvβ3  [98],  CNTO  95 
against both αvβ3 and αvβ5 [166], 17E6 against αvβ3, 
αvβ5 and αvβ1 [167]. Besides, antibodies targeting to 
other  integrins  have  been  developed.  For  example, 
Tysabri (natalizumab), an antibody which blocks α4 
integrins  and  inhibits  the  α4-mediated  adhesion  of 
leukocytes  to  their  counter  receptor  was  used  for 
treatment of patients with relapsing forms of multiple 
sclerosis  (MS)  [168].  Small  molecular  antagonists, 
mainly based on RGD containing peptides and RGD 
peptidomimetic [169-171], also showed potent inhibi-
tion of angiogenesis. More detailed information can 
be found in several recently published review articles 
[1, 172]. 
Integrin ligands are also under investigation as 
tumor  endothelium-targeted  diagnostic  agents  and 
integrin targeting is proving useful in tumor imaging. 
Both  peptide  and  antibody-based  diagnostic  agents 
targeting RGD-binding integrins or αv integrins have 
been evaluated in animal models of cancer after 18F or 
64Cu labeling. Tumor xenografts with positive integrin 
αvβ3 expression were visualized clearly on PET im-
ages [173-175]. Other imaging modalities besides PET 
have also been investigated for integrin αvβ3 targeted 
imaging.  For  example,  integrin  αv-targeted  ultra-
sound microbubbles preferentially bound neovascu-
lature at the periphery of experimental tumors [176]. 
The  clinical  significance  of  molecular  imaging  with 
integrin-targeting agents may be useful for lesion de-
tection  and  grading.  In  addition,  imaging  will  help 
identify  appropriate  patients  for  integrins  related 
therapy and monitor the therapeutic responses. More 
important,  integrin-targeting  agents  might  also  be 
useful in selectively delivering chemotherapeutics or 
gene therapeutic agents to tumors, thus minimizing 
systemic  toxicities.  For  example,  after  fused  with  a 
RGD  targeting  moiety,  RGD4C-TNF  showed  im-
proved tumor accumulation and therapy effect in a 
human breast tumor model [177].  
With regard to activity, signaling and regulation 
of  integrins,  evidences  are  accumulating  with  more 
crystal structures deciphered and new models estab-
lished. However, the integrin pathways are still not 
fully understood due to extreme complexity. Besides 
their ligands, increasing number of biomolecules has 
been  identified  interacting  with  integrins  including 
VEGF/VEGFR [178], HER2 [179], MMPs [180], uPAR 
[181]. Moreover, it has been found that ligand-bound 
integrins also actively suppress the activation of other Theranostics 2011, 1 
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integrins in the same cell utilizing different signaling 
pathways.  For example,  when α2β1 is  ligated, both 
α5β1  and  αVβ3  will  be  suppressed  through  PKA. 
When  α5β1  is  ligated,  α2β1  will  be  suppressed 
through PKCα [182]. Integrins are also known to have 
transdominant roles over other integrins and can thus 
control  overall  cell  behavior  [183].  After  epithelial 
integrity is restored in wounds, αvβ6 expression will 
be  strong  upregulated.  However,  mutating  the  β6 
cytoplasmic  domain  by  removing  the  terminal  11 
amino acids prevents this density-dependent upreg-
ulation of αvβ6 and replaces it by upregulating αvβ5. 
This provides evidence that  the expression  of these 
integrins is linked and expression may  be switched 
from one to the other [135]. 
So far, a lot of breakthroughs in integrin research 
have been made with purified integrins, or I-domains 
and their ligands.  However, it is becoming  increas-
ingly apparent that integrin mediated cell adhesion is 
unusually  complex.  Thus,  it  is  critical  to  study  the 
events occurring at the cellular and organism levels in 
a temporal manner to make more meaningful conclu-
sions. It is very promising for molecular imaging of 
living cells or animal models to meet the requirement. 
For example, microscopic imaging with FRET could 
identify  integrin-integrin  interaction  and  integ-
rin-other proteins interaction in living cells [184] [185]. 
PET  imaging  with  positron  emission  radioisotopes 
labeled integrin-targeting probes could visualize ex-
pression and regulation of integrins in animal models 
in a real-time mode [186]. We believe integrating data 
from both microscopic and macroscopic methods will 
quicken  our  steps  on  the  long  scientific  journey  to 
decipher the integrins related pathways.  
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